SAKAR HEALTHCARE Q2: GROSS PROFIT UP 53% YOY; ONCOLOGY BUSINESS GAINS MOMENTUM WITH GLOBAL REGULATORY APPROVALS

• Gross Profit: Up 53% YoY to ₹41.68 Cr in Q2; H1 gross profit up 57% YoY to ₹80.07 Cr • Oncology Contracts: Executed 69 oncology product contracts, with 45 additional commercial discussions underway • Global Filings: Shared 351 dossiers globally, with 191 submitted to regulatory agencies and 22 Marketing Authorisations (MAs) granted • International Approvals: Secured 11 MAs in Europe & UK, 6 in Latin America, 4 in APAC and 1 in Canada • European Expansion: Completed 36 EU marketing authorisation applications, including 16 own filings • Site Approvals: Submitted 33 site variations covering 18 oncology molecules, with 11 approvals in stringent EU and UK markets • Technology Transfers: 33 oncology product technology transfer projects underway with 4 partners • API Development: Developed 21 APIs in-house, with 8 products commercialised and 2 CEP applications approved • Commercial Supplies: Started domestic and international supplies from its EU GMP-approved, API-integrated oncology formulation facility • Accord Partnership: Received 6 additional EMA site variation approvals, taking total approvals to 8 of 11 molecules, alongside 3 additional approvals for other partners • Oncology Portfolio: Expanded treatment coverage across breast, lung, prostate, colorectal, blood and several other cancers

SAKAR HEALTHCARE LIMITED

← Back to feed